Effects of vector fusion peptides on the conformation and immune reactivity of epitope-shuffled, recombinant multi-epitope antigens

Protein and Peptide Letters

Volumn 18, Issue 1, 2011, Pages 73-83

  Wang, Jian ^a   Lin, Yahui ^a   Cai, Pengfei ^b   Wang, Heng ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b INSTITUTE OF PATHOGEN BIOLOGY   (China)

Author keywords

Conformation; Fusion peptide; Immunogenicity; Malaria; Multi epitope; Vaccine

Indexed keywords

EPITOPE; HYBRID PROTEIN; MALARIA VACCINE; PARASITE ANTIGEN;

AMINO ACID SEQUENCE; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BLOOD; CELLULAR IMMUNITY; CHEMISTRY; FEMALE; GENE VECTOR; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGY; MALARIA FALCIPARUM; MOLECULAR GENETICS; MOUSE; PLASMODIUM FALCIPARUM; PROTEIN SECONDARY STRUCTURE; RABBIT;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, PROTOZOAN; EPITOPES; FEMALE; GENETIC VECTORS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; MALARIA VACCINES; MALARIA, FALCIPARUM; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PLASMODIUM FALCIPARUM; PROTEIN STRUCTURE, SECONDARY; RABBITS; RECOMBINANT FUSION PROTEINS;

ANIMALIA; MURINAE; ORYCTOLAGUS CUNICULUS; PROKARYOTA;

EID: 78751519856     PISSN: 09298665     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986611794328690     Document Type: Article

References (27)

1. Ross, A. L.; Brave, A.; Scarlatti, G.; Manrique, A.; Buonaguro, L. Progress towards development of an HIV vaccine: Report of the AIDS Vaccine 2009 Conference. Lancet Infect. Dis., 2010, 10(5), 305-16.
2. Langhorne, J.; Ndungu, F. M.; Sponaas, A. M.; Marsh, K. Immunity to malaria: More questions than answers. Nat. Immunol., 2008, 9(7), 725-32.
3. Sacarlal, J.; Aide, P.; Aponte, J. J.; Renom, M.; Leach, A.; Mandomando, I.; Lievens, M.; Bassat, Q.; Lafuente, S.; Macete, E.; Vekemans, J.; Guinovart, C.; Sigauque, B.; Sillman, M.; Milman, J.; Dubois, M. C.; Demoitie, M. A.; Thonnard, J.; Menendez, C.; Ballou, W. R.; Cohen, J.; Alonso, P. L. Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children. J. Infect. Dis., 2009, 200(3), 329-36.
4. Bejon, P.; Lusingu, J.; Olotu, A.; Leach, A.; Lievens, M.; Vekemans, J.; Mshamu, S.; Lang, T.; Gould, J.; Dubois, M. C.; Demoitie, M. A.; Stallaert, J. F.; Vansadia, P.; Carter, T.; Njuguna, P.; Awuondo, K. O.; Malabeja, A.; Abdul, O.; Gesase, S.; Mturi, N.; Drakeley, C. J.; Savarese, B.; Villafana, T.; Ballou, W. R.; Cohen, J.; Riley, E. M.; Lemnge, M. M.; Marsh, K.; von Seidlein, L. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N. Engl. J. Med., 2008, 359(24), 2521-32.
5. Abdulla, S.; Oberholzer, R.; Juma, O.; Kubhoja, S.; Machera, F.; Membi, C.; Omari, S.; Urassa, A.; Mshinda, H.; Jumanne, A.; Salim, N.; Shomari, M.; Aebi, T.; Schellenberg, D. M.; Carter, T.; Villafana, T.; Demoitie, M. A.; Dubois, M. C.; Leach, A.; Lievens, M.; Vekemans, J.; Cohen, J.; Ballou, W. R.; Tanner, M. Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. N. Engl. J. Med., 2008, 359(24), 2533-44.
6. The PATH Malaria Vaccine Initiative. Phase 3 malaria vaccine trial begins-final testing of RTS,S. http://www.malariavaccine.org/ RTSSPhase3-05-27-2009.php(Accessed Jun 1, 2009).
7. Sagara, I.; Dicko, A.; Ellis, R. D.; Fay, M. P.; Diawara, S. I.; Assadou, M. H.; Sissoko, M. S.; Kone, M.; Diallo, A. I.; Saye, R.; Guindo, M. A.; Kante, O.; Niambele, M. B.; Miura, K.; Mullen, G. E.; Pierce, M.; Martin, L. B.; Dolo, A.; Diallo, D. A.; Doumbo, O. K.; Miller, L. H.; Saul, A. A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali. Vaccine 2009, 27(23), 3090-8.
8. Ogutu, B. R.; Apollo, O. J.; McKinney, D.; Okoth, W.; Siangla, J.; Dubovsky, F.; Tucker, K.; Waitumbi, J. N.; Diggs, C.; Wittes, J.; Malkin, E.; Leach, A.; Soisson, L. A.; Milman, J. B.; Otieno, L.; Holland, C. A.; Polhemus, M.; Remich, S. A.; Ockenhouse, C. F.; Cohen, J.; Ballou, W. R.; Martin, S. K.; Angov, E.; Stewart, V. A.; Lyon, J. A.; Heppner, D. G.; Withers, M. R. Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS One, 2009, 4(3), e4708.
9. Yang, T.; Wang, H. N.; Wang, X.; Tang, J. N.; Gao, R.; Li, J.; Guo, Z. C.; Li, Y. L. Multivalent DNA vaccine enhanced protection efficacy against infectious bronchitis virus in chickens. J. Vet. Med. Sci., 2009, 71(12), 1585-90.
10. Takala, S. L.; Plowe, C. V. Genetic diversity and malaria vaccine design, testing and efficacy: Preventing and overcoming 'vaccine resistant malaria'. Parasite Immunol., 2009, 31(9), 560-73.
11. Mahanty, S.; Saul, A.; Miller, L. H. Progress in the development of recombinant and synthetic blood-stage malaria vaccines. J. Exp. Biol., 2003, 206(Pt 21), 3781-8.
12. Shi, Q.; Lynch, M. M.; Romero, M.; Burns, J. M., Jr. Enhanced protection against malaria by a chimeric merozoite surface protein vaccine. Infect. Immun., 2007, 75(3), 1349-58.
13. Cai, Q.; Peng, G.; Bu, L.; Lin, Y.; Zhang, L.; Lustigmen, S.; Wang, H. Immunogenicity and in vitro protective efficacy of a polyepitope Plasmodium falciparum candidate vaccine constructed by epitope shuffling. Vaccine, 2007, 25(28), 5155-65.
14. Zhou, Z.; Todd, C. W.; Wohlhueter, R. M.; Price, A.; Xiao, L.; Schnake, P.; Bonner, P. C.; Martin, A. M.; Goldman, I. F.; De La Vega, P.; Udhayakumar, V.; Lal, A. A. Development, characterization and immunogenicity of a multi-stage, multi-valent Plasmodium falciparum vaccine antigen (FALVAC-1A) expressed in Escherichia coli. Hum. Vaccin., 2006, 2(1), 14-23.
15. McConkey, S. J.; Reece, W. H.; Moorthy, V. S.; Webster, D.; Dunachie, S.; Butcher, G.; Vuola, J. M.; Blanchard, T. J.; Gothard, P.; Watkins, K.; Hannan, C. M.; Everaere, S.; Brown, K.; Kester, K. E.; Cummings, J.; Williams, J.; Heppner, D. G.; Pathan, A.; Flanagan, K.; Arulanantham, N.; Roberts, M. T.; Roy, M.; Smith, G. L.; Schneider, J.; Peto, T.; Sinden, R. E.; Gilbert, S. C.; Hill, A. V. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med., 2003, 9(6), 729-35.
16. Livingston, B. D.; Newman, M.; Crimi, C.; McKinney, D.; Chesnut, R.; Sette, A. Optimization of epitope processing enhances immunogenicity of multi-epitope DNA vaccines. Vaccine, 2001, 19(32), 4652-60.
17. Ockenhouse, C. F.; Sun, P. F.; Lanar, D. E.; Wellde, B. T.; Hall, B. T.; Kester, K.; Stoute, J. A.; Magill, A.; Krzych, U.; Farley, L.; Wirtz, R. A.; Sadoff, J. C.; Kaslow, D. C.; Kumar, S.; Church, L. W.; Crutcher, J. M.; Wizel, B.; Hoffman, S.; Lalvani, A.; Hill, A. V.; Tine, J. A.; Guito, K. P.; de Taisne, C.; Anders, R.; Ballou, W. R.; et al. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J. Infect. Dis., 1998, 177(6), 1664-73.
18. Jiang, Y.; Lin, C.; Yin, B.; He, X.; Mao, Y.; Dong, M.; Xu, P.; Zhang, L.; Liu, B.; Wang, H. Effects of the configuration of a multi-epitope chimeric malaria DNA vaccine on its antigenicity to mice. Chin. Med. J., (Engl) 1999, 112(8), 686-90.
19. Qi, Y.; Zhang, B. Q.; Shen, Z.; Chen, Y. H. Candidate vaccine focused on a classical Swine Fever virus epitope induced antibodies with neutralizing activity. Viral Immunol., 2009, 22(3), 205-13.
20. Textoris-Taube, K.; Henklein, P.; Pollmann, S.; Bergann, T.; Weisshoff, H.; Seifert, U.; Drung, I.; Mugge, C.; Sijts, A.; Kloetzel, P. M.; Kuckelkorn, U. The N-terminal flanking region of the TRP2360-368 melanoma antigen determines proteasome activator PA28 requirement for epitope liberation. J. Biol. Chem., 2007, 282(17), 12749-54.
21. Le Gall, S.; Stamegna, P.; Walker, B. D. Portable flanking sequences modulate CTL epitope processing. J. Clin. Invest., 2007, 117(11), 3563-75.
22. Geldhof, P.; De Maere, V.; Vercruysse, J.; Claerebout, E. Recombinant expression systems: The obstacle to helminth vaccines? Trends Parasitol., 2007, 23(11), 527-32.
23. Cai, Q. L.; Wei, F.; Lin, Y. H.; Shao, D. D.; Wang, H. Immunogenicity of polyepitope libraries assembled by epitope shuffling: An approach to the development of chimeric gene vaccination against malaria. Vaccine, 2004, 23(2), 267-77.
24. Schlichtherle MWM, P. H., Scherf A. Methods in malaria research.3rd ed. Manassas, Virginia: MR4/ATCC Press;. 2000, p. 28-32.
25. Dalal, S.; Balasubramanian, S.; Regan, L. Protein alchemy: Changing beta-sheet into alpha-helix. Nat. Struct. Biol., 1997, 4(7), 548-52.
26. Service, R. F. Amino acid alchemy transmutes sheets to coils. Science, 1997, 277(5323), 179.
27. Minor, D. L., Jr.; Kim, P. S. Context-dependent secondary structure formation of a designed protein sequence. Nature, 1996, 380(6576), 730-4.